Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley L. Campbell sold 7,901 shares of the firm's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $11,083,175. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Amicus Therapeutics Price Performance
Shares of NASDAQ FOLD opened at $10.98 on Friday. The company has a market capitalization of $3.26 billion, a price-to-earnings ratio of -28.15 and a beta of 0.68. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The company has a 50 day simple moving average of $11.14 and a two-hundred day simple moving average of $10.61. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57.
There is a little known company that is changing warfare
From Reticulate | Ad
With geo - political instability around the world investors are flocking to defense contract stocks.
There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.
Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm's quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.15) earnings per share. Analysts expect that Amicus Therapeutics, Inc. will post -0.06 EPS for the current fiscal year.
Institutional Investors Weigh In On Amicus Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the company. OLD Second National Bank of Aurora bought a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. grew its position in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,569 shares during the period. Blue Trust Inc. grew its position in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,831 shares during the period. Arcadia Investment Management Corp MI bought a new stake in Amicus Therapeutics in the 3rd quarter worth approximately $32,000. Finally, Headlands Technologies LLC bought a new stake in Amicus Therapeutics in the 2nd quarter worth approximately $89,000.
Analyst Ratings Changes
FOLD has been the subject of a number of analyst reports. Cantor Fitzgerald increased their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Thursday. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a "buy" rating and a $18.00 target price for the company. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday. Guggenheim increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday. Finally, JPMorgan Chase & Co. dropped their target price on shares of Amicus Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a report on Friday, August 16th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $17.50.
Check Out Our Latest Report on FOLD
Amicus Therapeutics Company Profile
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
